OverviewSuggest Edit

RAPT Therapeutics (also known as FLX Bio) is a biopharmaceutical company that develops and commercializes immuno-oncology agents. The company is focused on developing molecule drugs which activate the immune system to eradicate cancer. Rapt Therapeutics also elaborates novel therapies to prolong the lives of people with cancer.

TypePublic
Founded2015
HQSouth San Francisco, CA, US
Websiterapt.com
Employee Ratings4.7

Latest Updates

Employees (est.) (Sept 2019)64
Job Openings5
Revenue (FY, 2020)$5 M
Share Price (Jul 2020)$27.6(-14%)
Cybersecurity ratingAMore

Key People/Management at RAPT Therapeutics

William Ho

William Ho

Chief Medical Officer
Rodney Young

Rodney Young

Chief Financial Officer
Brian Wong

Brian Wong

President and Chief Executive Officer, Director
David Wustrow

David Wustrow

Senior Vice President, Drug Discovery and Preclinical Development
Paul Kassner

Paul Kassner

Senior Vice President, Quantitative and Computational Biology
Dirk Brockstedt

Dirk Brockstedt

Chief Scientific Officer
Show more

RAPT Therapeutics Office Locations

RAPT Therapeutics has an office in South San Francisco
South San Francisco, CA, US (HQ)
561 Eccles Ave
Show all (1)

RAPT Therapeutics Financials and Metrics

RAPT Therapeutics Revenue

RAPT Therapeutics's revenue was reported to be $5.04 m in FY, 2020
USD

Revenue (Q1, 2021)

1.2m

Net income (Q1, 2021)

(16.5m)

EBIT (Q1, 2021)

(16.6m)

Market capitalization (13-Jul-2020)

671.5m

Closing stock price (13-Jul-2020)

27.6

Cash (31-Mar-2021)

24.7m
RAPT Therapeutics's current market capitalization is $671.5 m.
Annual
USDFY, 2017FY, 2018FY, 2020

Revenue

5.0m

General and administrative expense

3.7m5.2m12.8m

R&D expense

25.6m31.8m45.5m

Operating expense total

29.3m36.9m58.3m
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

Revenue

935.0k1.3m1.2m

General and administrative expense

1.7m3.3m2.8m4.0m

R&D expense

8.6m10.7m11.0m13.8m

Operating expense total

10.3m14.0m13.8m17.8m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

47.5m63.8m77.4m24.9m

Prepaid Expenses

725.0k1.3m3.1m4.1m

Current Assets

48.2m65.1m80.5m115.6m

PP&E

1.9m4.2m3.7m3.0m
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

48.3m91.5m29.0m24.7m

Accounts Receivable

5.0m

Prepaid Expenses

2.9m3.7m3.1m4.2m

Current Assets

51.2m146.9m136.1m102.6m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(29.1m)(36.1m)(43.0m)(52.9m)

Depreciation and Amortization

1.4m1.2m1.3m1.1m

Accounts Payable

(80.0k)1.5m736.0k2.4m

Cash From Operating Activities

(27.1m)(33.0m)(35.5m)(40.5m)
Quarterly
USDQ3, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(29.8m)(13.1m)(25.5m)(16.5m)

Depreciation and Amortization

1.0m199.0k595.0k280.0k

Accounts Payable

2.2m2.4m1.8m362.0k

Cash From Operating Activities

(29.8m)(8.7m)(15.2m)(13.9m)
USDFY, 2017

Financial Leverage

1.1 x
Show all financial metrics

RAPT Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

RAPT Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

RAPT Therapeutics Online and Social Media Presence

Embed Graph

RAPT Therapeutics News and Updates

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in onco…

RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis

•  Improvements demonstrated in all key exploratory efficacy endpoints - percent change in EASI, EASI-50, vIGA and pruritis NRS - at four weeks following once-daily oral treatment with RPT193•  Further improvement in percent change in EASI, EASI-50 and vIGA observed with RPT193 two weeks after end o…

RAPT Therapeutics Reports First Quarter 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncol…

RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dermatitis

Company Reaffirms Guidance to Report Data in 1H 2021 Company Reaffirms Guidance to Report Data in 1H 2021

RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results

SOUTH SAN FRANCISCO, Calif., March 11, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in onc…

RAPT Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in onco…
Show more

RAPT Therapeutics Blogs

RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares Content Import Fri, 06/18/2021 - 12:25 RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Op…

RAPT Therapeutics Announces Proposed Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., June 14, 2021 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in

RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis

RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis Content Import Sun, 06/13/2021 - 16:01 RAPT Therapeutics to Report Top Line Data from Phase 1b Trial of RPT193 in Atopic Dermatitis June 13, 2021 This release is a ba…

RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference

RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference Content Import Thu, 05/20/2021 - 16:00 RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference May 20, 2021 This release is a backfill from a News Wire …

RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR

RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR Content Import Wed, 03/10/2021 - 16:30 RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR Ma…

RAPT Therapeutics to Participate in Two Investor Conferences in March

RAPT Therapeutics to Participate in Two Investor Conferences in March Content Import Wed, 03/03/2021 - 08:00 RAPT Therapeutics to Participate in Two Investor Conferences in March March 3, 2021 This release is a backfill from a News Wire …
Show more

RAPT Therapeutics Frequently Asked Questions

  • When was RAPT Therapeutics founded?

    RAPT Therapeutics was founded in 2015.

  • Who are RAPT Therapeutics key executives?

    RAPT Therapeutics's key executives are William Ho, Rodney Young and Brian Wong.

  • How many employees does RAPT Therapeutics have?

    RAPT Therapeutics has 64 employees.

  • What is RAPT Therapeutics revenue?

    Latest RAPT Therapeutics annual revenue is $5 m.

  • What is RAPT Therapeutics revenue per employee?

    Latest RAPT Therapeutics revenue per employee is $78.8 k.

  • Who are RAPT Therapeutics competitors?

    Competitors of RAPT Therapeutics include Kiromic Biopharma, XBiotech and Dragonfly.

  • Where is RAPT Therapeutics headquarters?

    RAPT Therapeutics headquarters is located at 561 Eccles Ave, South San Francisco.

  • Where are RAPT Therapeutics offices?

    RAPT Therapeutics has an office in South San Francisco.

  • How many offices does RAPT Therapeutics have?

    RAPT Therapeutics has 1 office.